 Substituted N-carboxymethyl-aminoacylaminoalkanoic acids useful as antihypertensive agents |
| OF THE INVENTION AND PREFERRED EMBODIMENTS In its broadest aspect, the present invention relates ... |
|
| Racemates of optically active bicyclic imino-alpha-carboxylic esters |
| We claim: 1. A diasteromic salt of i. a bicyclic imino-.alpha.-carboxylic ester of the formulae Ia ... |
|
| Disubstituted proline derivatives |
| We claim: 1. A compound of the formula I ##STR15## in which R.sup.1 and R.sup.2 together represent ... |
|
| Carboxyalkyl dipeptides and anti-hypertensive use thereof |
| We claim: 1. A compound represented by the formula ##STR12## and the pharmaceutically acceptable ... |
|
| Optically active bicyclic imino-alpha-carboxylic esters |
| We claim: 1. A compound of the formulae Ia or Ib essentially free of its racemate, and salts of ... |
|
| 5-HT.sub.3 receptor antagonists for treatment of cough and bronchoconstriction |
| I claim: 1. A method of treatment of cough and/or bronchoconstriction in mammals, which method ... |
|
| Therapeutic compositions with enhanced bioavailability |
| OF THE INVENTION This invention relates to compositions of a drug with a water soluble polymer ... |
|
| Medicament adsorbates and their preparation |
| In particular, it has been found that a good tasting medicament adsorbate is produced from ... |
|
| Sustained release formulations |
| We claim: 1. In combination, a drug suitable for oral delivery and a delivery system for sustained ... |
|
|
Formulations providing three distinct releases
| Details |
|
Inventors: Mehta, Atul M.; Bachand, Lizbeth A.; Leonard, Thomas W.; Warner, Ronald N.;
Assignee: American Home Products Corporation (New York, NY)
Primary Examiner: Rose; Shep K.
Assistant Examiner:
Attorney, Agent or Firm: Routh; John W.
A therapeutic preparation consisting of three groups of spheroids containing an active medicinal substance. The first group of spheroids is uncoated and rapidly disintegrates upon ingestion to release an initial dose of medicinal substance a second group of spheroids is coated with a pH sensitive coat to provide a second dose and a third group of spheroids is coated with a pH independent coat to provide a third dose. A powder blend of active medicinal substance may be substituted for the first group of uncoated spheroids. The therapeutic preparation may be utilized as a mixture of groups of spheroids in a capsule. |
|
DETAILED DESCRIPTION We claim: 1.
A therapeutic composition for oral administration consisting essentially of a pharmaceutical gelatin capsule containing film coated spheroids, which spheroids prior to coating comprise 10% to 60% by weight of an vinpocetine in admixture with non-water swellable microcrystalline cellulose, and said film coating comprising (i) an undercoat selected from the group consisting of hydroxypropyl methylcellulose and hydroxypropyl methylcellulose containing as a disintegrant carboxymethylcellulose sodium or sodium starch glycolate and (ii) an overcoat consisting of a copolymer based on polymethyacrylic acid esters containing metalic stearates.
2.
A therapeutic composition for once daily oral administration consisting essentially of a pharmaceutical gelatin capsule containing a powder blend of vinpocetine and two groups of coated spheroids each also containing vinpocetine wherein: (a) said powder blend comprises 10% to 50% by weight of vinpocetine in admixture with pharmaceutical excipients for immediate release of vinpocetine to provide a loading dose of vinpocetine, (b) said first group of spheroids comprises film coated spheroids, which spheroids prior to coating comprise 20% to 75% by weight of vinpocetine in admixture with non-water swellable cellulose, said film coating comprising (i) a copolymer based on methacrylic acid and methacrylic acid methyl ester or (ii) polyvinyl acetate phthalate, said first group of film coated spheroids having a pH sensitive coating to provide a delayed second dose of vinpocetine, and (c) said second group of spheroids comprises film coated spheroids, which spheroids prior to coating comprise 10% to 60% by weight of vinpocetine in admixture with non-water swellable microcrystalline cellulose, and said film coating comprising (i) an undercoat selected from the group consisting of hydroxypropyl methylcellulose and hydroxypropyl methylcellulose containing as a disintegrant carboxymethylcellulose sodium or sodium starch glycolate and (ii) an overcoat consisting of a neutral copolymer based on polymethacrylic acid esters containing metallic stearates, said second group of film coated spheroids being double coated with an effective thickness to provide a further delayed third dose of vinpocetine
|
| Related patents |
|
|
Floating sustained release therapeutic compositions
OF THE INVENTION According to the present invention, therapeutic dosage forms have now been discovered which are easy to prepare, provide sustained release of contained ...
|
|
|
Solid oral dosage forms of ifosfamide
OF PREFERRED EMBODIMENTS The invention is illustrated by the following examples: EXAMPLE 1 Ifosfamide capsule mass In accordance with the invention, the capsule mass is ...
|
|
|
[(benzodioxan, benzofuran or benzopyran) alkylamino] alkyl substituted guanidines
We claim: 1. A compound of the formula: ##STR259## a pharmaceutically acceptable acid addition salt thereof, or a stereochemically isomeric form thereof, wherein: X is O,...
|
|
|
Methods for treating dermatitis using descarboethoxyloratadine
OF THE INVENTION The present invention encompasses a method of treating allergic asthma in a human while avoiding the concomitant liability of adverse side-effects ...
|
|
|
Fat emulsions containing isocarbacyclin
What is claimed is: 1. A pharmaceutical prostaglandin emulsion comprising: a mixture of vegetable oil, phospholipid, water, and a pharmaceutically effective amount of at ...
|
|
|
Dermal pharmaceutical preparations
OF THE INVENTION The support which can be used in the present invention functions to retain a layer of a pressure-sensitive adhesive containing a drug and is selected ...
|
|
|
Substituted iminodiacids, their preparation and pharmaceutical compositions containing them
We claim: 1. A compound selected from the group consisting of iminodiacid compounds having the formula: ##STR20## wherein R.sub.1 represents lower-alkyl having 1 to 4 ...
|
|
|
2-Azasfiro[4.(3+N)]-3-carboxylic acid derivatives, a process for their preparation, agents containing these derivatives and their use
We claim: 1. A compound of the formula I ##STR11## in which n denotes 1, 2, 3 or 4, R denotes (C.sub.1 -C.sub.6)-alkyl, (C.sub.2 -C.sub.6)-alkenyl, (C.sub.5 -C.sub.9)-...
|
|
|
N-Acyl hexahydroindole-2-carboxylic acids and anti-hypertensive use thereof
We claim: 1. A compound of the formula I, ##STR24## in which n denotes 0 to 1, R denotes hydrogen, (C.sub.1 to C.sub.6)-alkyl or aralkyl having 7 to 9 C atoms, R.sup.1 ...
|
|
|
Bicyclic amino acids as intermediates in the preparation of tricyclic amino acids and processes for their preparation
We claim: 1. A compound of the formula III ##STR19## in which A denotes --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --, the H atoms on C-2 and C-6 are in the cis-...
|
|
|
Vasodialators 
